Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Eton, Omar ^a   Ross, Merrick I ^a   East, Mary J ^a   Mansfield, Paul F ^a   Papadopoulos, Nicholas ^a   Ellerhorst, Julie A ^a   Bedikian, Agop Y ^a   Lee, Jeffrey E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ALPHA2 INTERFERON; ANTINEOPLASTIC AGENT; GAMMA INTERFERON; INTERLEUKIN 2; VITESPEN; CANCER VACCINE; HEAT SHOCK PROTEIN;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; AUTOTRANSPLANTATION; BLURRED VISION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CELL COUNT; CELLULAR IMMUNITY; CONSTIPATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE COURSE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; INTERFERON PRODUCTION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NAUSEA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN TEST; TUMOR VOLUME; VIRUS REACTIVATION; VISION; VITILIGO; ANIMAL; CLINICAL TRIAL; CYTOLOGY; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ANIMALS; CANCER VACCINES; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIERS ESTIMATE; LEUKOCYTES, MONONUCLEAR; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; YOUNG ADULT;

EID: 77649306333     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-9     Document Type: Article

References (28)

1. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997, 278:117-120. 10.1126/science.278.5335.117, 9311915.
2. Blachere NE, Udono H, Janetzki S, Li Z, Heike M, Srivastava PK. Heat shock protein vaccines against cancer. J Immunother 1993, 14:352-356.
3. Srivastava PK, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994, 39:93-98. 10.1007/BF00188611, 8276462.
4. Suto RSP. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995, 269:1585-1588. 10.1126/science.7545313, 7545313.
5. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001, 14:303-313. 10.1016/S1074-7613(01)00111-X, 11290339.
6. Gordon NF, Clark BL. The challenges of bringing autologous HSP-based vaccines to commercial reality. Methods 2004, 32:63-69. 10.1016/S1046-2023(03)00188-9, 14624879.
7. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000, 88:232-238. 10.1002/1097-0215(20001015)88:2<232::AID-IJC14>3.0.CO;2-8, 11004674.
8. Handbook for reporting results of cancer treatment. 1979, WHO, Geneva.
9. Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M, Scita G, Santantonio C, Pilla L, Tragni G, Lombardo C, Arienti F, Marchiano A, Queirolo P, Bertolini F, Cova A, Lamaj E, Ascani L, Camerini R, Corsi M, Cascinelli N, Lewis JJ, Srivastava P, Parmiani G. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002, 20:4169-4180. 10.1200/JCO.2002.09.134, 12377960.
10. Catalona WJ, Taylor PT, Rabson AS, Chretien PB. A method for dinitrochlorobenzene contact sensitization - A clinicopathological study. NEJM 1972, 286:399-402.
11. Eilber FR, Nizze JA, Morton DL. Sequential evaluation of general immune competence in cancer patients: correlation with clinical course. Cancer 1975, 35:660-665. 10.1002/1097-0142(197503)35:3<660::AID-CNCR2820350319>3.0.CO;2-X, 234294.
12. Camacho ES, Pinsky CM, Braun DW, Golbey RB, Fortner JG, Wanebo HJ, Oettgen HF. DNCB reactivity and prognosis in 419 patients with malignant melanoma. Cancer 1981, 47:2446-2450. 10.1002/1097-0142(19810515)47:10<2446::AID-CNCR2820471023>3.0.CO;2-V, 7272900.
13. Czerkinsky C, Nilsson L, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983, 65:109-21. 10.1016/0022-1759(83)90308-3, 6361139.
14. Lewis JJ, Janetzki S, Schaed S, Panageas KS, Wang S, Williams L, Meyers M, Butterworth L, Livingston PO, Chapman PB, Houghton AN. Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer 2000, 87:391-8. 10.1002/1097-0215(20000801)87:3<391::AID-IJC13>3.0.CO;2-K, 10897045.
15. Eton O, Kharkevitch DD, Gianan MA, Ross MI, Itoh K, Pride MW, Donawho C, Buzaid AC, Mansfield PF, Lee JE, Legha SS, Plager C, Papadopoulos NE, Bedikian AY, Benjamin RS, Balch CM. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. Clin Cancer Res 1998, 4:619-627.
16. Wells AD. New Insights into the Molecular Basis of T Cell Anergy: Anergy Factors, Avoidance Sensors, and Epigenetic Imprinting. J Immunology 2009, 182:7331-7341.
17. Salerno-Goncalves R, Pasetti MF, Sztein MB. Characterization of CD8(+) effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J Immunol 2002, 169:2196-2203.
18. Morton DL, Mozzillo N, Thompson JF, Kelley MC, Faries M, Wagner J, Schneebaum S, Schuchter L, Gammon G, Elashoff R, . MMAIT Clinical Trials Group I An international, randomized, phase III trial of Bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. Proc Am Soc Clin Oncol 2007, 25. abstract 8508, MMAIT Clinical Trials Group I.
19. Buseyne F, Scott-Algara D, Porrot F, Corre B, Bellal N, Burgard M, Rouzioux C, Blanche S, Riviere Y. Frequencies of ex vivo-activated human immunodeficiency virus type 1-specific gamma-interferon-producing CD8(+) T cells in infected children correlate positively with plasma viral load. J Virol 2002, 76:12414-12422. 10.1128/JVI.76.24.12414-12422.2002, 136692, 12438567.
20. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002, 3:611-618. 10.1038/ni0702-611, 12087419.
21. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001, 167:1137.
22. Amato R, Wood L, Savary C, Wood C, Hawkins E, Reitsma D, Srivastava P. Patients with Renal Cell Carcinoma Using Autologous Tumor-Derived Heat Shock Protein-Peptide Complex (HSPPC-96) With or Without Interleukin-2. Proc Am Soc Clin Oncol 2000, 19. abstr 1782.
23. Baker-LePain JC, Reed RC, Nicchitta CV. ISO: a critical evaluation of the role of peptides in heat shock/chaperone protein-mediated tumor rejection. Curr Opin Immunol 2003, 15:89-94. 10.1016/S0952791502000067, 12495739.
24. Flynn GC, Chappell TG, Rothman JE. Peptide binding and release by proteins implicated as catalysts of protein assembly. Science 1989, 245:385-390. 10.1126/science.2756425, 2756425.
25. Beckmann RP, Mizzen LE, Welch WJ. Interaction of Hsp 70 with newly synthesized proteins: implications for protein folding and assembly. Science 1990, 248:850-854. 10.1126/science.2188360, 2188360.
26. Frydman J, Nimmesgern E, Ohtsuka K, Hartl FU. Folding of nascent polypeptide chains in a high molecular mass assembly with molecular chaperones. Nature 1994, 370:111-117. 10.1038/370111a0, 8022479.
27. Fewell SW, Travers KJ, Weissman JS, Brodsky JL. The action of molecular chaperones in the early secretory pathway. Annu Rev Genet 2001, 35:149-191. 10.1146/annurev.genet.35.102401.090313, 11700281.
28. Suzue K, Zhou X, Eisen HN, Young RA. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci USA 1997, 94:13146-13151. 10.1073/pnas.94.24.13146, 24277, 9371814.